培美替尼使用指南:适应症及用法用量介绍

Introduction: Pemetinib is a kinase inhibitor indicated for the treatment of previously treated adult patients with locally advanced or metastatic, unresectable cholangiocarcinoma. Pemetinib is taken orally, and patients should take medication under the guidance of a doctor. This article will introduce in detail the indications, usage and dosage of pemetinib.

Indications and uses of pemetinib

In April 2020, it was approved by the FDA for the treatment of adult patients with previously treated unresectable locally advanced or metastatic cholangiocarcinoma who have been tested for fibroblast growth factor receptor 2 (FGFR2) gene fusion or other rearrangement and have been approved by the FDA. The FDA-approved indication for pemigatinib was granted accelerated approval based on overall response rate and duration of response in premarket clinical trials.

Usage and Dosage

Pemetinib is provided in the form of tablets. Patients need to take it orally and swallow the entire tablet with water, with or without food. The recommended dose of pemetinib is 13.5 mg, taken continuously for 14 days and then stopped for 7 days, with a cycle of 21 days.

Clinical trial efficacy

A study evaluated the efficacy of pemetinib. 107 patients received pemetinib 13.5 mg orally once a day for 14 days and then stopped for 7 days. The efficacy endpoints were overall response rate (ORR) and duration of response (DOR). The study results showed that the ORR of patients treated with pemetinib was 36%, and the median DOR was 9.1 months.

Safety Analysis

The most common adverse reactions during pemetinib treatment are nausea, constipation, stomatitis, dry eyes, dry mouth, hyperphosphatemia, decreased appetite, vomiting, alopecia, diarrhea, nail toxicity, hypophosphatemia, dysgeusia, fatigue, joint pain, abdominal pain, back pain, and dry skin. Ocular toxicity and hyperphosphatemia are important risks with pemetinib.

Lifestyle Care

Cholangiocarcinoma is a rare cancer that forms in the bile ducts, the long, thin tubes that carry digestive bile from the liver to the gallbladder and small intestine. During treatment with pemetinib, patients should pay attention to monitoring adverse reactions and conduct regular reexaminations. Choose easily digestible, nutrient-dense foods such as lean meats, fish, eggs, dairy products, fresh fruits and vegetables, and whole grains. Encourage patients to express their emotions and relieve fear, anxiety and depression through communication with family, friends or professional psychological counselors.